UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Clinical cancer research, 2006-09, Vol.12 (17), p.5064-5073

2006

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

Clinical cancer research, 2003-09, Vol.9 (11), p.4247-4254

2003

Volltextzugriff (PDF)

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

Clinical cancer research, 2004-05, Vol.10 (9), p.3216-3224

2004

Volltextzugriff (PDF)

Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma

Journal of clinical oncology, 2003-02, Vol.21 (4), p.646-651

2003

Volltextzugriff (PDF)

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Nature, 2006-12, Vol.444 (7120), p.756-760

2006

Volltextzugriff (PDF)

Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa)

Clinical cancer research, 2002-11, Vol.8 (11), p.3496-3502

2002

Volltextzugriff (PDF)

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

Clinical cancer research, 2005-11, Vol.11 (22), p.8145-8157

2005

Volltextzugriff (PDF)

Oncolytic polio virotherapy of cancer

Cancer, 2014-11, Vol.120 (21), p.3277-3286

2014

Volltextzugriff (PDF)

Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer

Clinical cancer research, 2003-11, Vol.9 (15), p.5514-5520

2003

Volltextzugriff (PDF)

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

Blood, 2011-09, Vol.118 (11), p.3003-3012

2011

Volltextzugriff (PDF)

Colocalization of Gadolinium-Diethylene Triamine Pentaacetic Acid With High-Molecular-Weight Molecules After Intracerebral Convection-Enhanced Delivery in Humans

Neurosurgery, 2011-09, Vol.69 (3), p.668-676

2011

Volltextzugriff (PDF)

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv

International journal of cancer, 2000-12, Vol.88 (6), p.962-969

2000

Volltextzugriff (PDF)

Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft

Clinical cancer research, 2000-10, Vol.6 (10), p.4154-4157

2000

Volltextzugriff (PDF)

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[ 211At]astato-3-pyridinecarboxylate

Nuclear medicine and biology, 1999-05, Vol.26 (4), p.405-411

1999

Volltextzugriff (PDF)

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Journal of clinical oncology, 2000-11, Vol.18 (22), p.3862-3872

2000

Volltextzugriff (PDF)

Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

Nuclear medicine and biology, 2010-10, Vol.37 (7), p.741-750

2010

Volltextzugriff (PDF)

Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas : Laboratory investigation

Journal of neurosurgery, 2008-02, Vol.108 (2), p.330-335

2008

Volltextzugriff (PDF)

Temozolomide Delivered by Intracerebral Microinfusion is Safe and Efficacious Against Malignant Gliomas in Rats

Clinical cancer research, 2000-10, Vol.6 (10), p.4148-4153

2000

Volltextzugriff (PDF)

Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate

Nuclear medicine and biology, 2002, Vol.29 (1), p.1-11

2002

Volltextzugriff (PDF)

Regional Treatment of Epidermal Growth Factor Receptor vIII-expressing Neoplastic Meningitis with a Single-Chain Immunotoxin, MR-1

Clinical cancer research, 1999-09, Vol.5 (9), p.2646-2652

1999

Volltextzugriff (PDF)

Mutations of the BRAF gene in human cancer

Nature (London), 2002-06, Vol.417 (6892), p.949-954

2002

Volltextzugriff (PDF)

Treatment of Neoplastic Meningitis with Intrathecal Temozolomide

Clinical cancer research, 1999-05, Vol.5 (5), p.1183-1188

1999

Volltextzugriff (PDF)

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Cancer Immunology, Immunotherapy, 2002-02, Vol.50 (12), p.639-652

2002

Volltextzugriff (PDF)

Positively charged templates for labeling internalizing antibodies : comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR

Nuclear medicine and biology, 2001-10, Vol.28 (7), p.769-777

2001

Volltextzugriff (PDF)

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

Blood, 2004-08, Vol.104 (3), p.642-648

2004

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Aktive Filter

KollektionAmerican Association for the Advancement of Science

Zeitschrift / SerieCancer Research

ThemaTumors Of The Nervous System. Phacomatoses

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(85)

Publikationsform

Artikel
(92)

Sprache

Englisch
(92)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Epidermal Growth Factor Receptor VIII Peptide Vaccination Is Efficacious against Established Intracerebral Tumors

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

Brain Tumors in Mice Are Susceptible to Blockade of Epidermal Growth Factor Receptor (EGFR) with the Oral, Specific, EGFR-Tyrosine Kinase Inhibitor ZD1839 (Iressa)

ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors

Oncolytic polio virotherapy of cancer

Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer

Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans

Colocalization of Gadolinium-Diethylene Triamine Pentaacetic Acid With High-Molecular-Weight Molecules After Intracerebral Convection-Enhanced Delivery in Humans

Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII‐specific scFv

Schedule-dependent Activity of Temozolomide plus CPT-11 against a Human Central Nervous System Tumor-derived Xenograft

Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[ 211At]astato-3-pyridinecarboxylate

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands

Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas : Laboratory investigation

Temozolomide Delivered by Intracerebral Microinfusion is Safe and Efficacious Against Malignant Gliomas in Rats

Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate

Regional Treatment of Epidermal Growth Factor Receptor vIII-expressing Neoplastic Meningitis with a Single-Chain Immunotoxin, MR-1

Mutations of the BRAF gene in human cancer

Treatment of Neoplastic Meningitis with Intrathecal Temozolomide

Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system

Positively charged templates for labeling internalizing antibodies : comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR

Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma

Aktive Filter

Suchergebnisse filtern